Previous 10 | Next 10 |
Edward J. Delaney, an American author who’s written fictional books such as “Follow the Sun” and “Warp and Weft,” recently published a new novel based on the life of Cary Grant. The novel in question, “ The Acrobat ,” focuses on Grant’...
The Women in Psychedelics Network (“ WIPN ” or “ Network ”), a network of professionals from all corners of the psychedelic industry strengthening women’s voices and providing opportunities to move mental health solutions forward, today announc...
atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company that specializes in the use of psychedelics to treat mental health conditions, saw its shares rise 14.58% on Tuesday. The stock closed at $2.95 on Monday then opened on Tuesday at $3.15. The stock ros...
Certain events bring about volatility that creates massive opportunities for traders on either side of the screen. That’s exactly what happened on Tuesday after a Berlin-based %Biotech company announced it plans to announce its third quarter 2022 financial results and business up...
For more than a year, a palliative care specialist has been fighting to be granted permission by the U.S. Drug Enforcement Administration (DEA) to administer psilocybin to his patients. Dr. Sunil Aggarwal had requested a federal waiver under the Right to Try statute , which would have all...
NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthc...
Loop Capital has initiated Atai Life Sciences ( NASDAQ: ATAI ) as a buy saying that the company's candidates provide a unique way to invest in psychedelic treatments for mental health illnesses. The firm has an $18 price target (~510% upside based on Monday's close). S...
NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its third quarter 2022 financial results and busin...
Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine). Last patient expected to be dosed this week, with the total number of patients expected to be around 100. Topline results expected around year-...
NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day. During this ...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...